Zantac / Ranitidine (NDMA Cancer) Attorney in Omaha, Nebraska

Zantac Litigation in Omaha

Omaha's large insurance and finance sector workforce — centered around Berkshire Hathaway and Mutual of Omaha — has comprehensive employer pharmacy benefit records documenting long-term ranitidine use. Nebraska's 4-year product liability SOL provides a broader filing window than most states. Nebraska applies Daubert under Neb. Rev. Stat. § 27-702. Omaha-area claimants should consult national plaintiffs' counsel about Delaware Superior Court filing. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Resources for Omaha Zantac Claimants

Omaha-area Zantac claimants should gather pharmacy records from Hy-Vee Pharmacy, Walgreens, CVS, and employer pharmacy benefit programs. UNMC Buffett Cancer Center and Nebraska Medicine records documenting bladder, esophageal, stomach, or colorectal cancer are critical evidence. Nebraska's 4-year SOL provides more time than most states — consult qualified Zantac counsel promptly.